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For the diagnosis of reﬂex syncope, diligent history-building with the patient and awitness is required. In the
Emergency Department (ED), the assessment of syncope is a challenge which may be addressed by an ED
Observation Unit or by a referral to a Syncope Unit. Hospital admission is necessary for those with life-
threatening cardiac conditions although risk stratiﬁcation remains an unsolved problem. Other patients may
be investigated with less urgency by carotid sinus massage (440 years), tilt testing, and electrocardiogram
loop recorder insertion resulting in a clear cause for syncope. Management includes, in general terms, patient
education, avoidance of circumstances in which syncope is likely, increase in ﬂuid and salt consumption, and
physical counter-pressure maneuvers. In older patients, those that will beneﬁt from cardiac pacing are now
well deﬁned. In all patients, the beneﬁt of drug therapy is often disappointing and there remains no ideal
drug. A role for catheter ablation may emerge for the highly symptomatic reﬂex syncope patient.
& 2017 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the CC
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Much has been written on the diagnosis and treatment of reﬂex
syncope. This review will attempt to offer emphasis on new
aspects and approaches. Syncope is a common symptom thatblished by Elsevier B.V. This is an
ogy, Hammersmith Hospital,affects approximately 40% of humans during a lifetime [1]. Many
episodes are unreported or are seen later by family physicians
who, in the majority of cases, appropriately offer only reassurance
[2]. More concerning episodes arrive in the Emergency Depart-
ment (ED) accounting for about 1% of the workload [3]. In many
countries attendance at the ED is followed by hospital admission
as an inpatient for a costly attempt at diagnosis of the cause of
syncope which often fails to yield the diagnosis sought [4]. In this
unsatisfactory state of affairs, there is subsequent recurrence of
syncope and mortality that is potentially avoidable [5].open access article under the CC BY-NC-ND license
R. Sutton / Journal of Arrhythmia 33 (2017) 545–552546The justiﬁcation for the study of syncope is its common
occurrence, frequent misdiagnosis, and mismanagement.2. Methods
A PubMed search was conducted using the terms ‘Syncope’,
‘Reﬂex Syncope’, ‘Diagnosis of Reﬂex Syncope’, and ‘Treatment of
Reﬂex Syncope’. The selected articles from this search plus my
own database act as the basis for this review.Fig. 1. Causes of syncope. Adapted from Moya et al. [3]. Abbreviations: ANS,
autonomic nervous system; AV, atrioventricular; CSS, carotid sinus syndrome; Diss.,
dissection; HCM, hypertrophic cardiomyopathy; LQTS, long QT syndrome; MI,
myocardial infarction; SVT, supraventricular tachycardia; VT, ventricular tachy-
cardia; VVS, vasovagal syncope.3. Diagnosis of syncope
The diagnosis of syncope is clinical in the ﬁrst instance which
is demanding of the physician to address in a thorough, time-
consuming, and detailed fashion. Without such an approach,
there can be no clinically valuable result. This is not modern
medicine, as is generally seen, but old-fashioned ‘slow’ medicine.
As well as the details of all events experienced by the patient
from beginning to end, a careful assessment of medication his-
tory including diet with special attention to ﬂuid and salt con-
sumption, activity, patient's background, and past medical his-
tory and family history are required [6]. Leading questions must
be avoided, and when something does not ﬁt into a pre-
conceived pattern, it should not be ignored. When attacks are
multiple, it may help to ask a family member or friend to record
an attack on a cell phone. An appreciation of the circulatory
physiology underlying the symptoms is essential to their full
understanding. In the case of syncope, much anxiety is embodied
in the patient and the family because of the drama of the event. It
is necessary for the physician to understand this and to keep it in
mind throughout the analysis of the symptom. An approach of
this nature will gain the conﬁdence of the patient, lead to more
important details being revealed, and the enhancement of the
doctor-patient relationship which is very essential during the
possible tribulations of the treatment phase [6,7].
3.1. Transient loss of consciousness
Transient loss of consciousness (TLoC) will be reported by an
observer or by the patient. It is necessary to determine the cause of
the TLoC. There are three categories that are pertinent. First,
concussion causes TLoC, but in such cases, trauma is usually evi-
dent before the TLoC, and the loss of conscious may be of a longer
duration than that of a typical syncope which is 1–2 min. The
second group of TLoC presentations is composed of syncope and
epileptic seizures. An initial consideration is that syncope pre-
senting in the ED is approximately 10 times more common than is
epileptic seizure. The differential diagnosis between syncope and
epilepsy has recently been reviewed by Sheldon [8]. Separation is
of great importance as substantial numbers of patients have been
shown to be attending epilepsy clinics where the diagnosis is
reﬂex syncope [9]. Both reﬂex syncope and epilepsy carry risk to
the patient in the short- and long-term, emphasizing the impor-
tance of correct diagnosis. The third category is syncope mimics
which are mainly psychogenic pseudosyncope (PPS). These two
latter categories will receive more attention and in doing so, a
deﬁnition of syncope is helpful. This deﬁnition is now accepted in
Europe [3] and in North America [10].
3.2. Syncope deﬁnition
Syncope is a syndrome in which loss of consciousness is of
relatively sudden onset, temporary (usually o1–2 min), self-ter-
minating, and of usually rapid recovery. It is due to inadequatecerebral perfusion most often caused by a fall in systemic arterial
pressure.
3.3. Causes of syncope
The causes of syncope are many and these are laid out in Fig. 1.
Physicians attending patients with syncope are required to
know these causes and consider them. The Figure has been
modiﬁed from that in the European Society of Cardiology (ESC)
Guidelines to include adenosine-related syncope, but since this is
not considered to be a reﬂex syncope, it is not covered in this
article. Reﬂex syncope includes vasovagal syncope (VVS), situa-
tional syncope, and carotid sinus syndrome (CSS).
Having ﬁrst determined from the patient's history and a wit-
ness account that the episode was TLoC and subsequently deter-
mined that it was syncope, with further probing by history taking,
better termed history-building, the cause of syncope can be
determined in up to 90% of cases. The history from a witness is as
important as the history from the patient because the patient can
tell us nothing about the period of loss of consciousness. A witness
may not necessarily attend the hospital with the patient but may
often be reached by cell phone. This must be part of the history-
building. History-building is an old technique of bringing the
patient into a face-to-face discussion of what happened with
interest, empathy, and enthusiasm shown by the physician in
contrast to today's norm of a physician, invisible to the patient
behind a computer, bawling out questions with great rapidity, and
barely listening to the answers. The slow and empathetic approach
not only builds the history but also builds the doctor-patient
relationship [7,11]. The two aims of history-building are (1) to
identify the speciﬁc cause and mechanism of the event in order to
apply effective treatment, and (2) to assess the prognostic risk
including death, severe adverse events, and syncope recurrence.
For syncope, interrogation must begin with how the day star-
ted, for example, was the patient tired on arising from bed? The
role of triggers must be probed. Details of the prodrome must be
collected. The unconscious period will be reported by the witness
and the patient will explain how the recovery and the remainder
of the day were. This is the required level of detail for each and
every attack [6,7,11].
Syncope has a bimodal distribution through life with peaks in
teenage years and when old, rising progressively beyond 40 years
Table 1
Predisposing factors for syncope. Adapted from Sutton et al. [6].
Volume depletion (blood loss, dehydration, diarrhea/vomiting, sweating);
High ambient temperature;
Conﬁned spaces;
Crowding;
Emotional circumstances;
Pain;
Menstrual period;
Hypocapnia;
Hypoxia;
Fever;
Rapid weight loss;
Alcohol intake (usually small quantities);
Insufﬁcient food, Starvation, Anorexia nervosa;
Sleep deprivation, Tiredness;
Prolonged bed rest;
Prolonged weightlessness;
Boredom;
After strenuous exercise;
During exposure to high G-forces;
Medication such as beta-blockers, vasodilators, and diuretics
Table 2
Triggers for syncope. Adapted from Sutton et al. [6].
Typical reﬂex syncope
Prolonged standing;
Pain/invasive procedures;
Emotion: sight of blood, injury to oneself or to others, stress;
Post-exercise;
Situational syncope
Gastro-intestinal (GI): swallowing, colic, defecation, GI tract instrumentation
Urogenital (UG): micturition, vaginal examination, prostate examination/mas-
sage, UG tract instrumentation;
Eyeball pressure;
Respiratory: Cough, sneeze, laugh, wind-instrument paying, singing, weight-
lifting, mess trick, stretching
Table 3
Indications for hospital admissions. Adapted from the European Society of Car-
diology Guidelines 2009 [3].
FOR DIAGNOSIS
Suspected or known important heart disease
ECG suggesting arrhythmic syncope
Syncope during exercise
Syncope causing severe injury
Family history of sudden unexpected death at o40 years
Syncope when supine
FOR TREATMENT
Life-threatening arrhythmia
Syncope related to structural cardiopulmonary disease
CIED implantation required
OTHER REASONS
Sudden palpitation before syncope
High suspicion of cardiac syncope
Recurrent episodes
Lack of available home-care
Abbreviations: CIED, cardiac implantable electronic device; ECG, electrocardiogram.
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drome, no family history of sudden death, and a normal exam-
ination and ECG [6,7,11]. Older people may have known heart
disease, an abnormal examination and/or ECG, and less often a
trigger and a prodrome. Amnesia for the event increases with age
[12]. This is important because the older patient may present with
an unexplained fall.
Tables 1 and 2 show a list of predisposing factors and triggers
which will prompt appropriate questions. The list is inevitably
incomplete because of the diversity of possible presentations but
offer areas of exploration with every patient.
The clinical history is the ﬁrst part of the ESC Guideline
recommendation for the initial evaluation [3]. After the history, a
routine physical examination should be performed, paying special
attention to the presence of left ventricular hypertrophy, cardiac
murmurs, and neurological deﬁcits. These do not require high-
level acumen in the physical examination. Blood pressure
recordings are required while lying, standing, and standing after
3 min to detect abnormalities or notably orthostatic hypotension.
Abnormalities on the 12-lead ECG such as left ventricular hyper-
trophy and old or fresh myocardial infarction can usually be
readily seen. More subtle abnormalities such as prolonged QT
interval and Brugada syndrome pattern may require cardiological
help. Today, almost all ECG machines have an electronic reporting
system. These are very accurate in terms of duration of ECG
intervals and highly dependable at separating normality from
abnormality. Thus, they can be very helpful to non-cardiologists at
an early stage of assessment, for example, in the ED. They should
not be expected to make diagnoses such as Brugada syndrome.When the initial assessment is completed by an experienced
physician but not a syncope expert, approximately 60% of patients
may have their cause of syncope identiﬁed [13]. The age of the
patient is inﬂuential in this context as 68% of young patients are
correctly labelled, in contrast only 54% of older patients are diag-
nosed [13]. The history may be assisted by use of a questionnaire
although this is more appropriate in an outpatient setting than in
the ED. This could be termed Phase 1 of the history-building
process. In the ED, a computer driven program [14] may be a way
of facilitating Phase 2 in tandem with the emergency physician's
assessment of the patient. This step will allow patients to be
divided into those with a known benign cause who can be dis-
charged with a follow-up appointment in a syncope clinic or with
a syncope specialist. If the cause of syncope is determined to be
potentially dangerous, the patient will require hospital admission
for observation or treatment (ideally 20% of all). The remaining
patients without a clinical diagnosis at this stage (intermediate
group) require risk stratiﬁcation to decide on management [15].
This is a controversial area as no fool-proof system currently exists.
The Canadian Cardiovascular Society's attempt at this is generally
considered the best yet available [16].
For patients presenting to the ED without a ﬁrm diagnosis
emanating from the initial evaluation, two approaches have been
advocated. The ﬁrst is temporary admission to an observation unit
in or close to the ED where patients can be monitored and
assessed for up to 24 h [17]. The second is early referral to a
Syncope Unit which has full capability for investigation and
diagnosis [18]. The former is efﬁcient and expensive. Although ﬁrst
published in 2004 [17], data obtained from the ED observation
unit has not been widely accepted and only recently offered
additional favorable data [19]. The second, the syncope clinic, has
had more acceptance and is not very expensive, but even in Eur-
ope where acceptance is currently the greatest, such units are by
no means ubiquitous.
Table 3 provides guidance on which patients require hospital
admission with the remainder being managed more con-
servatively [3]. If the diagnosis remains elusive, the ideal approach
is for a syncope specialist to see the patient, with a rate of diag-
nosis of 90% [13]. This is Phase 3, but it is unrealistic to think that a
syncope specialist is available in every ED 24 h per day as there are
too few of them. When an attempt at diagnosis is made, the rate of
diagnoses improves [20].
A syncope specialist is someone who has a broader knowledge
beyond that of syncope. Considering that the patient may present
with TLoC, the specialist must possess extensive experience with
TLoC patients by continuous learning from clinical practice,
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edge in the specialty, listening to other experts, and consistently
exhibiting superior performance in the management of patients
with TLoC [6,7,11]. A trainee can learn to be a syncope specialist by
learning from patients; gaining clinical experience; reading papers
by experts; seeking a mentor, even by email; watching syncope
specialists in action, when possible; leaning from Neurologists,
Internists, Pediatricians, and Geriatricians as they see different
patients and each has a different approach; and learning from ED
specialists as their approach is completely different [6,7,11].
3.4. Diagnosis of syncope by investigations
When the diagnosis is impossible by means of the ESC-
recommended initial evaluation [3], investigations must be
entertained. These are mostly directed toward the intermediate-
risk group. It is assumed that high-risk patients have been exclu-
ded. In the intermediate-risk group, the ﬁrst consideration is car-
otid sinus massage in patients over the age of 40 years. It is
advised that this is carried out in the tilt laboratory in both supine
and upright positions with 10 s of massage on the right carotid
artery in the neck followed by the left artery in both positions. It is
further recommended to use the ‘method of symptoms’ as intro-
duced originally by Brignole's group [21]. If the massage is posi-
tive, with reproduction of symptoms, in a patient presenting with
syncope, a diagnosis of CSS is made. A positive ﬁnding with
asystole of 43 s (cardioinhibition) and reproduction of syncope
should be followed by treatment with dual chamber pacing. A
positive ﬁnding with hypotension (vasodepression) and repro-
duction of syncope should be followed by a different treatment
[22].
The second consideration is a tilt test as this is an inexpensive
and helpful test. When reﬂex syncope is suspected, the tilt test is
likely to conﬁrm the diagnosis. However, this test has additional
beneﬁts as follows: (1) The patient will experience usual symp-
toms during the attack and be able to conﬁrm that these are
similar to what has previously happened. Thus, this will be a
learning experience for the patient taking place in a clinical
environment rather than the real world. (2) The patient will
understand that the diagnosis of the previous episode(s) is clear to
the treating team and conﬁdence will be built. (3) Other condi-
tions will, if pertinent, be revealed such as orthostatic hypoten-
sion, postural orthostatic tachycardia, and PPS. (4) The presence of
tilt positivity with reproduction of symptoms in older patients
points to a less favorable result of pacing therapy. In this area, tilt
testing is a risk of recurrence stratiﬁcation tool (please refer to
Section 4.1) [22].
The third step is insertion of an ECG loop recorder (ILR) sub-
cutaneously. These devices are battery powered and last 3 years
providing very high quality ECG monitoring. Further, they can be
accessed through the same wireless systems as are used for
pacemaker and deﬁbrillator follow-up. Thus, they offer very close
follow-up and permit rapid action should a further syncope be
recorded which demands intervention, such as pacing [3]. The
tendency, driven by serial ESC reports [3,23,24] is to bring the ILR
forward to an earlier point in the management of the
intermediate-risk group. The above discussion also deliberately
describes the SUP-2 (syncope unit project) recommendations of
how to manage an older patient with likely reﬂex syncope [25,26].
This Italian syncope unit group of 10 centers has combined to
formulate a policy as enumerated above and put it into practice.
The results will be discussed later.
Other investigations are seldom needed. Exercise testing may
be valuable if symptoms occur in relation to exercise (3). Echo-
cardiography is indicated when there is any clinical suggestion of a
cardiac abnormality. Coronary angiography is indicated on usualgrounds. Electrophysiological studies (EPS) have little role in
patients yet undiagnosed. However, they may prove useful in
conﬁrmation of an arrhythmia recorded by an ILR or other means.
In bradyarrhythmias, documentation of sinoatrial disease and
demonstration of His-Purkinje disease are the two areas of
greatest potential. For ventricular tachycardia, an implantable
cardioverter deﬁbrillator may be indicated without the need for an
EPS [3]. Both EPS and tilt are affected by their inability to offer a
deﬁnitive diagnosis in many cases where they appear to be
required. Tilt has been condemned as inaccurate by the United
Kingdom body, National Institute of Clinical Excellence, but they
failed to comprehend what tilt positivity really is, as argued by
Brignole and Sutton [22]: a demonstration of a vasodepressor or
hypotensive tendency.
Managing younger patients with reﬂex syncope in terms of
diagnosis will not include carotid sinus massage but will likely
adopt the second and third steps as described above. There is a
considerable weight of evidence supporting the use of ILRs for
precise diagnosis in both young and old patients [27–31]. The
diagnostic yield is around 35% in the ﬁrst year and may rise as high
as 80% in 4 years [32]. In contrast, it is necessary to state clearly
that there are many tests still frequently used across the world
which have almost no value in diagnosis at all. These include
electroencephalogram, brain scanning by computed tomography
or magnetic resonance, carotid ultrasound, Holter monitoring,
exercise testing except when symptoms are related to exercise,
and coronary angiography [3].
Situational syncope is a subdivision of reﬂex syncope. Reﬂexes
are involved, but each type of situational syncope has its own
proﬁle. These have recently been classiﬁed [6]. Some are very
inclusive in this category placing such syncope as that which
occurs after exercise, during blood donation, and during eating.
This is not valuable in my view. The common situational syncopes
are while coughing, at medical instrumentation, and during or
after urination. These truly involve triggers and are very dynamic,
natural autonomic events. There is usually a considerable overlap
with vasovagal syncope. Each situational syncope must be inves-
tigated as usual by history-building in order draw a correct picture
of the type of reﬂex involved. For example, cough syncope almost
always involves vasodepression with little cardioinhibitory com-
ponent [33]. Micturition syncope more often involves some
cardioinhibition.
3.5. Cardiac disease and coincidence with reﬂex syncope
The common occurrence of VVS makes it extremely likely that
patients with heart disease, both structural and arrhythmic may
also suffer VVS raising an important challenge to the physician.
Here is an area where it might be hoped that tilt testing will be a
valuable discriminatory test. Unfortunately, this is not the case as
tilt testing is revealing a hypotensive or vasodepressor tendency
that is intrinsic and may or may not reveal the etiology of the
patient's presenting episode [17]. Understanding this brings ben-
eﬁt in terms of risk stratiﬁcation of recurrence during subsequent
therapy but no beneﬁts in terms of diagnosis of syncope cause in
heart disease.
3.6. Psychogenic pseudosyncope
This condition is classiﬁed as a syncope mimic. PPS has been
known for a long time and was probably the so-called swoon of
19th century novels. In medical terms, it was suspected but infre-
quently diagnosed until the advent of physiological monitoring
during a maneuver likely to precipitate syncope in potentially
susceptible subjects such as tilt testing. The condition was found in
a few tilted patients with heart rate and arterial pressure
R. Sutton / Journal of Arrhythmia 33 (2017) 545–552 549monitoring and clearly identiﬁed because there was no fall in
heart rate and no fall in blood pressure at the time of apparent
syncope [34,35]. Later, much more detailed studies including
continuous electroencephalographic monitoring, showing little
change in contrast to the typical and dramatic pattern of VVS,
allowed a full description of the syndrome [36]. Collapses due to
VVS and PPS have occurred during the same tilt test, raising a
possibility that some of the events of the syncope are sub-
consciously learnt by the patient. In PPS, the patient appears to
lose consciousness but has no color change and closed eyes. There
is a modest tachycardia preceding and coinciding with the event
[36]. The clinical presentation is typically with a great number of
syncope episodes, some of which may present as rather active
syncope, for example, an almost active fall [30]. The combination
of a detailed history and a tilt test showing no blood pressure fall, a
slight tachycardia, and a normal electroencephalogram makes the
diagnosis of PPS.
Regarding the causes of syncope, in approximately 10% or more
of patients, there is no diagnosis. Eventually, the diagnosis is likely
to reveal itself and be benign in nature.4. Management
The term management is more accurate than treatment which
implies that there is effective treatment for reﬂex syncope. Cur-
rently, there are some methods of management, but regrettably,
no widely agreed speciﬁc treatments. This, however, should not be
surprising because in reﬂex syncope, we are trying to treat an
intrinsic tendency that probably exists in all humans, manifesting
itself in a mere 40% of the population [1]; this tendency that may
evolve over decades to become what we normally call a disease
[37,38]. Many treatments have been attempted aiming at different
points in the assumed reﬂex arc, but there has been little success.
Management must begin with patient education (Table 4). It is
important that the patient understands what an attack is and the
difﬁculties that exist in managing the condition. The message that
attacks are not mortal is essential information for the patient and
family. In cases where there is warning, there are some effective
ways of management. The ﬁrst is to be aware of the potential for
an attack, keeping in mind previous circumstances and feelings.
Evasive action is then possible. For example, leaving the room,
sitting down, and drinking cold water can all be helpful, but such
measures are often taken too late to have any beneﬁt. The second
is use of counter-pressure maneuvers. These involve a form ofTable 4
Available therapy for reﬂex syncope.
Therapy Proof of efﬁcacy Which patients?
Explanation None All
Counter-Pres. Good Warning required
Fluid increase Little All
Salt increase Little All except HBP
Beta-blockers None None
Adrenergic Some Frequent syncope not responding to GM
SSRIs None None
Fluid-retaining Some Frequent syncope not responding to GM
Ivabradine None Tachycardia pre-syncope
Tilt-training Little Any patient willing
Cardiac pacing Some Older patients with documented
brady/asyst
Catheter ablation Little Very severely affected
Abbreviations/deﬁnitions: Adrenergic, midodrine and droxidopa; Any patient
willing, any patient who is motivated to comply with the therapeutic protocol;
Brady/asyst, intense bradycardia or asystole; Counter-pres. Counter pressure
maneuvers; Fluid-retaining, ﬂudrocortisone; GM, general measures (upper 4 in this
Table); HBP, hypertension; SSRIs, selective serotonin reuptake inhibitors.isometric exercise which includes linking ﬁngers and attempting
to pull them apart without letting go, crossing the legs and
squeezing them together, buttock tensing, and squatting. All these
measures can be useful, but they must be employed as soon as
warning signs are present. The literature supports these man-
euvers [39,40] but they are likely to be ineffective in older people
with less muscle power and bulk as was shown in an ISSUE-3 sub-
study (International study of syncope of unknown etiology) [41].
General useful advice may have some beneﬁt such as drinking
more water and increasing salt consumption. The aim is to
increase blood volume. Three liters of water per day and at least
6 g of salt are the usual recommendations. There is little scientiﬁc
evidence to support this. Caffeine is a diuretic and works, to an
extent, to oppose the ﬂuid and salt recommendations. Thus, it
seems reasonable to reduce caffeine consumption but, again, there
is no scientiﬁc evidence in its favor.
Beyond these measures, drugs are the other option, but they
should be considered with reluctance. With drugs, treatment
must be taken continuously because of the unpredictable nature
of the attacks. Very frequent VVS occurs on six occasions per
year [42], therefore, in such cases medication is taken on 359
days when it was not needed. Medications have side-effects
which, if prominent, could easily outweigh any available beneﬁt.
Moreover, an important percentage of patients is female and of
child bearing age, so drugs must have no teratogenic effects.
Drugs considered in the past have been beta-blockers on which
there have been numerous randomized controlled trials [43–
47], but all except one showed no beneﬁt. The trial showing a
positive result in favor of the selected beta-blocker [43] was
ﬂawed as the trial lasted only 1 month, and repeat tilt testing
was the main end-point. The ESC has strongly recommended [3]
against repeat tilt testing to demonstrate the effect of therapy
prompted by a study of midodrine by Moya and colleagues [48]
and the VASIS trial of dual-chamber pacing versus no treatment
in VVS [49], as in both trials, the protocol-determined repeat tilt
testing gave misleading results.
Midodrine, an alpha-adrenergic drug, has some mildly encoura-
ging trial data [50–52], but no trial was sufﬁciently powered. It is a
drug frequently selected today. It has many clinical disadvantages
which include its short half-life requiring administration at least
3 times daily, its complete lack of teratogenic data, and its tendency
to cause urinary retention in older male subjects. Its problems of lack
of availability and United States Food and Drug administration
approval have largely been overcome. Fludrocortisone seems to be a
logical therapy to increase blood volume. No trial has been convin-
cing until the Prevention of syncope trial (POST-2). This trial was
sufﬁciently large but gave only weakly positive results [53]. Never-
theless, it is also a drug frequently selected to treat patients today.
Ivabradine has some adherents, but, as yet, no trial has been
undertaken. If a trial of this drug were to be mounted, it would
have to address only those patients in whom a tachycardia
can be demonstrated before VVS by tilt or on ILR. Ivabradine
can attenuate this and in so doing might be preventative of
syncope [54].
Other drugs have been tried and have failed. These include
etilefrine and droxidopa, alpha adrenergic agonists, and selective
serotonin reuptake inhibitors for which one small trial showed
some beneﬁt not supported by other work. All, except droxidopa,
for which little data yet exists, are summarized in the 2009 ESC
Guidelines [3].
Tilt training is among other techniques that have been reported
and attempts to re-educate the autonomic nervous system by
prolonged periods of standing [55]. The results available do not yet
support its wide acceptance [3]. Another technique is intracardiac
catheter ablation of ganglionic plexi on the epicardial surface of
the heart [56–58]. A limited number of very symptomatic patients
R. Sutton / Journal of Arrhythmia 33 (2017) 545–552550have had their symptoms well controlled, but to date, there is no
randomized controlled trial.
4.1. Treatment of vasovagal syncope by pacing
From the inception of tilt testing to diagnose VVS [59], atten-
tion has been focused on the possibility that pacing could provide
control and relief because of the dramatic and severe associated
symptoms of asystole in VVS. An early series report was
encouraging [60], prompting randomized controlled trials. The
ﬁrst two to be published were the Vasovagal pacemaker study-1
(VPS-1) [61] and Vasovagal Syncope International study (VASIS)
[49]. These trials of small sample size seemed promising, but their
protocols were ﬂawed because pacemaker therapy was compared
with no therapy or atenolol [62], and the favorable results were
quickly explained by a placebo effect on the operated patients.
Further trials were warranted, and in VPS-2 [63] together with the
syncope and pacemaker trial (SYNPACE) [64], pacemakers were
implanted in all patients of whom approximately half in each trial
were randomized to being switched to a sensing-only mode.
Neither trial showed any beneﬁt for active pacing.
The next phase in the study of the possible beneﬁt of pacing
was to turn attention to patient selection. This was done initially in
the International study of syncope of unknown etiology (ISSUE-2)
[29] by implantation of ILRs in all patients. Those whose sponta-
neous attacks were bradycardiac could be paced in this registry.
Approximately half of those patients received pacing, and their
outcomes were much better than those of patients who were not
paced. These results prompted the ISSUE-3 trial [65] where a clear
and signiﬁcant beneﬁt in terms of syncope recurrence was
demonstrated for those paced in comparison with the other half of
the group whose devices were in sensing-only mode. Recurrence
of syncope in 2 years was 24% with pacing and 57% without pacing
(po0.039). This was the ﬁrst pacemaker trial to show unequivocal
beneﬁt for pacing in older reﬂex syncope (not CSS) patients.
A striking ﬁnding [66], when follow-up was extended and
registry patients refusing randomization were included, was that a
positive pre-implant tilt test indicated a high likelihood of syncope
recurrence not signiﬁcantly different from no pacing. On the other
hand, a negative pre-implant tilt implied excellent symptom
control with 5% recurrence in 21 months. The implications of this
result were interpreted by Sutton and Brignole [22]. The sub-
sequent study Syncope Unit Project-2 (SUP-2) [25,26] has strongly
supported the initial conclusions, although the results of pacing
those with a positive tilt pre-implant seem better than those in the
ISSUE-3 trial [65].
Thus, it can now be stated that, in older patients with non-CSS
reﬂex syncope with documented bradycardia in spontaneous
attacks by ILR, a tilt test should be performed prior to implant to
risk stratify the likelihood of syncope recurrence. Further, many of
these patients are taking hypotensive medications that probably
exacerbate their tendency to syncope recurrence implying that
these drugs may have to be withdrawn or reduced in dosage. More
studies are required in this area.
It must be emphasized that, while pacing is a valuable therapy,
it is indicated for a very small percentage of those presenting
recurrent syncope. Second, the results will be less effective for
some patients. Third, the mode of assessing the need for and the
delivery of pacing is still controversial. Most implanted devices
rely on the onset of bradycardia to trigger pacing. It is well known
that bradycardia follows hypotension in almost all VVS cases [67].
Therefore, this method leaves much to be desired and there may
be better options; one method that is currently available detects
reducing right ventricular volume (reﬂecting diminishing venous
return) and increase in ventricular contractility (reﬂecting rise incirculating epinephrine) and is currently being evaluated in a
randomized controlled trial (BIOPACE-Biotronik).
4.2. Treatment of carotid sinus syndrome
For patients with documented cardioinhibitory CSS, the treat-
ment of choice is dual-chamber pacing [3,68]. Good results can be
expected in terms of syncope recurrence. As CSS is not considered
to be mortal, symptom control is the aim. However, it must now be
recommended that prior to implantation the patient undergoes a
tilt test. If positive, more syncope recurrence must be expected
than if the test is negative [17,69,70]. The SUP-2 studies [25,26]
give the most up-to-date and useful information about what can
be expected in practice.
There was a hope in the early years of this millennium that
carotid sinus hypersensitivity (CSH) (patients with positive carotid
sinus massage but having no symptoms and no deﬁnite syncope)
presenting with unexplained falls could be treated with pacing. It
was anticipated that CSH was a precursor of CSS, but this has not
yet been established. Unfortunately, after the ﬁrst encouraging
trial [71] subsequent trials with more patients and more sophis-
ticated protocols were unable to conﬁrm the early results [72,73].
Research in this area has now switched to inserting an ILR in
patients with unexplained falls. In a pilot study, a high incidence of
arrhythmias was found, many of which are likely to have been of
reﬂex origin [74].
Treatment of vasodepressor CSS is similar to that of dominantly
vasodepressor VVS including ﬂuids, increase in salt consumption if
the patient is not hypertensive, and drugs such as midodrine but
with great care in male patients or ﬂudrocortisone. In hyperten-
sive patients, the ﬁrst step is to reduce hypotensive medication
[75]. As for VVS, the result of treatment tends to leave much to be
desired. Support hose and abdominal binding might be useful in
an uncontrolled case.
4.3. Treatment of situational syncope
Treatment of situational syncope depends totally on the pre-
senting pathophysiology of the syncope. For example, the vaso-
depression of cough syncope may be the target for therapy, but in
ideal circumstances the cough itself should be addressed. In mic-
turition syncope, considerations are, for male patients, to urinate
in the sitting position together, if necessary, with physical counter-
pressure maneuvers. Situational syncope is rarely dominantly
cardioinhibitory, implying that pacing is seldom required. The
principles of treatment, however, are the same as in VVS.
4.4. General considerations
Syncope as a symptom causes much anxiety in the patient and
family. This prompts consultation particularly if the symptom
presents in a cluster as is quite common in VVS. The fact that the
symptom tends to resolve spontaneously over time should not be
surprising. Sheldon's group has recently studied the phenomenon
of ‘reversion to the mean’ in the context of syncope [76]. This
aspect must be taken into account when making major manage-
ment decisions.Conﬂict of interest
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